Literature DB >> 2857336

Intravenous IgG for patients with spontaneous inhibitor to Factor VIII.

R Zimmermann, B Kommerell, J Harenberg, W Eich, K Rother, K Schimpf.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2857336     DOI： 10.1016/s0140-6736(85)91046-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

Review 1.  Intravenous immunoglobulin therapy for acquired coagulation inhibitors: a critical review.

Authors:  Koji Yamamoto; Junki Takamatsu; Hidehiko Saito
Journal:  Int J Hematol       Date:  2007-05       Impact factor: 2.490

2.  Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies.

Authors:  J G Gilles; J M Saint-Remy
Journal:  J Clin Invest       Date:  1994-10       Impact factor: 14.808

Review 3.  Intravenous immunoglobulin (IVIG) for the therapy of autoimmune disorders.

Authors:  S A Schwartz
Journal:  J Clin Immunol       Date:  1990-03       Impact factor: 8.317

4.  Successful treatment with high-dose intravenous immunoglobulin in a patient with spontaneous inhibitor to factor VIII.

Authors:  E Hiller; E Holler; R G Geursen; H Riess
Journal:  Blut       Date:  1986-02

5.  Immediate effects of intravenous IgG administration on peripheral blood B and T cells and polymorphonuclear cells in patients with myasthenia gravis.

Authors:  L Cook; J F Howard; J D Folds
Journal:  J Clin Immunol       Date:  1988-01       Impact factor: 8.317

Review 6.  Intravenous immune globulins. A review of their uses in selected immunodeficiency and autoimmune diseases.

Authors:  B Pirofsky; D M Kinzey
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

7.  Anti-idiotypes against autoantibodies and alloantibodies to VIII:C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins.

Authors:  F Rossi; Y Sultan; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.